SHANGHAI, China, Jan. 6 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services, announced today that Mr. Cuong Viet Do will temporarily assume the role of the Chairman of the Audit Committee until a permanent successor is appointed.
The Chairman of the Audit Committee was previously held by Mr. Shawn Wang who recently passed away in an accident during his vacation.
Mr. Cuong Viet Do has served as an independent director on WuXi PharmaTech's Board of Directors since July 2007 and is a member of the Audit Committee. Mr. Do is currently the chief strategy officer of Lenovo Group Limited. Mr. Do joined Lenovo in 2006 after 17 years at McKinsey & Company, where he was Director and senior partner. During his tenure at McKinsey, he consulted with leading companies in 18 countries and four continents on issues involving strategy, sales and marketing, operations, and corporate finance. Mr. Do was a leader of McKinsey's Corporate Finance practice and was responsible for training all of McKinsey's consultants on Finance and M&A topics. At different stages of his career at McKinsey, Mr. Do helped build and was a leader in the healthcare, high tech, and marketing practices. Mr. Do has more than a decade experience working with pharmaceutical and medical device companies around the world in R&D, sales and marketing, licensing & acquisitions, and operations. He has also served hospitals and governments on healthcare policy.
Mr. Do has a bachelor's degree in Biochemistry and Economics from Dartmouth College and a master's degree in Business Administration from the Tuck School of Business Administration, where he now serves on the MBA Board. He also serves on the boards of several non-profit groups, including Celebrate the Children, a school for autistic children, and the National Youth Science Foundation.
About WuXi PharmaTech
Founded in 2000, Shanghai-based WuXi PharmaTech is the leading
China-based pharmaceutical and biotechnology R&D outsourcing company. As a
research- driven and customer-focused company, WuXi PharmaTech provides
pharmaceutical and biotechnology companies a broad and integrated portfolio
of laboratory and research manufacturing services throughout the drug
discovery and development process. WuXi PharmaTech's services are designed
to assist its global partners in shortening the cycle and lowering the cost
of drug discovery and development by providing cost-effective and efficient
outsourcing solutions that save its customers both time and money. Its
operations are grouped into two segments: laboratory services, consisting
of discovery chemistry, service biology, analytical, toxicology,
pharmaceutical development and process development services, and research
manufacturing, focusing on manufacturing of advanced intermediates and
active pharmaceutical ingredients for R&D use. In 2007, its 80 customers
included nine of the world's top ten pharmaceutical companies by revenue.
For more information, please visit: http://www.wuxipharmatech.com .
For more information, please contact:
|SOURCE WuXi PharmaTech|
Copyright©2008 PR Newswire.
All rights reserved